191 related articles for article (PubMed ID: 14729652)
1. Effector cell-derived lymphotoxin alpha and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Hylind JC; Dutton RW
Cancer Res; 2004 Jan; 64(1):406-14. PubMed ID: 14729652
[TBL] [Abstract][Full Text] [Related]
2. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
3. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 1999 Jun; 162(11):6671-80. PubMed ID: 10352285
[TBL] [Abstract][Full Text] [Related]
5. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2000 Jan; 164(2):916-25. PubMed ID: 10623840
[TBL] [Abstract][Full Text] [Related]
6. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors.
Helmich BK; Dutton RW
J Immunol; 2001 Jun; 166(11):6500-8. PubMed ID: 11359800
[TBL] [Abstract][Full Text] [Related]
7. The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis.
Hollenbaugh JA; Reome J; Dobrzanski M; Dutton RW
J Immunol; 2004 Aug; 173(3):1738-43. PubMed ID: 15265903
[TBL] [Abstract][Full Text] [Related]
8. CD8Tc1 and Tc2 cells secrete distinct cytokine patterns in vitro and in vivo but induce similar inflammatory reactions.
Li L; Sad S; Kägi D; Mosmann TR
J Immunol; 1997 May; 158(9):4152-61. PubMed ID: 9126975
[TBL] [Abstract][Full Text] [Related]
9. Perforin-independent CD8(+) T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-alpha: relative insensitivity to Fas ligand.
Liu AN; Mohammed AZ; Rice WR; Fiedeldey DT; Liebermann JS; Whitsett JA; Braciale TJ; Enelow RI
Am J Respir Cell Mol Biol; 1999 May; 20(5):849-58. PubMed ID: 10226053
[TBL] [Abstract][Full Text] [Related]
10. CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer.
Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA
J Immunol; 2006 Dec; 177(11):8191-201. PubMed ID: 17114496
[TBL] [Abstract][Full Text] [Related]
11. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
13. Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes.
Vukmanovic-Stejic M; Vyas B; Gorak-Stolinska P; Noble A; Kemeny DM
Blood; 2000 Jan; 95(1):231-40. PubMed ID: 10607707
[TBL] [Abstract][Full Text] [Related]
14. Cytokine-deficient CD8+ Tc1 cells induced by IL-4: retained inflammation and perforin and Fas cytotoxicity but compromised long term killing of tumor cells.
Sad S; Li L; Mosmann TR
J Immunol; 1997 Jul; 159(2):606-13. PubMed ID: 9218575
[TBL] [Abstract][Full Text] [Related]
15. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
16. Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
Clin Immunol; 2001 Jan; 98(1):70-84. PubMed ID: 11141329
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity and weak CD40 ligand expression of CD8+ type 2 cytotoxic T cells restricts their potential B cell helper activity.
Sad S; Krishnan L; Bleackley RC; Kägi D; Hengartner H; Mosmann TR
Eur J Immunol; 1997 Apr; 27(4):914-22. PubMed ID: 9130644
[TBL] [Abstract][Full Text] [Related]
18. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
Winter H; Hu HM; Urba WJ; Fox BA
J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
[TBL] [Abstract][Full Text] [Related]
19. Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen.
Prévost-Blondel A; Neuenhahn M; Rawiel M; Pircher H
Eur J Immunol; 2000 Sep; 30(9):2507-15. PubMed ID: 11009083
[TBL] [Abstract][Full Text] [Related]
20. CD8+ T cell subsets TC1 and TC2 cause different histopathologic forms of murine cardiac allograft rejection.
Delfs MW; Furukawa Y; Mitchell RN; Lichtman AH
Transplantation; 2001 Mar; 71(5):606-10. PubMed ID: 11292288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
